Impact of Ketamine on Opioid Use and Persistent Pain After Cytoreductive Surgery with Hyperthermic Chemotherapy
Juan P Cata,Pascal Owusu-Agyemang,Dhanalakshmi Koyyalagunta,German Corrales,Lei Feng,Keith Fournier
DOI: https://doi.org/10.2147/JPR.S311995
IF: 2.8319
2021-08-13
Journal of Pain Research
Abstract:Juan P Cata, 1, 2 Pascal Owusu-Agyemang, 1, 2 Dhanalakshmi Koyyalagunta, 3 German Corrales, 1, 2 Lei Feng, 4 Keith Fournier 2, 3 1 Department of Anesthesiology and Perioperative Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 2 Anesthesiology and Surgical Oncology Research Group, Houston, TX, USA; 3 Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 4 Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA Correspondence: Juan P Cata Department of Anesthesiology and Perioperative Medicine, The University of Texas MD Anderson Cancer Centre, Houston, TX, USA Tel +1 713-792-4582 Fax +1 713-792-4582 Email Background: Persistent pain and opioid use can be devastating after cytoreductive surgery (CRS) and hyperthermic intraoperative chemotherapy (HIPEC). Methods: We conducted a retrospective study to investigate the impact of ketamine use on postoperative complications and persistent and chronic pain after CRS-HIPEC. Results: Ketamine reduced perioperative opioid use before and after implementation of recovery after surgery programs. Ketamine did not impact the formation of persistent and chronic pain formation and long-term opioid use. Postoperative complications and postoperative re-operations were independent predictors of persistent pain. Interestingly, the risk of having a complication was increased by 1% for every doubling in opioids used intraoperatively. Conclusion: Ketamine use reduces perioperative opioid consumption in patients undergoing CRS-HIPEC, but it is not associated with improvements in long-term opioid use and chronic pain. Keywords: chronic pain, cancer, neoplasm, opioids, ketamine, surgery, cytoreductive surgery Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is increasingly offered as a treatment option for patients with peritoneal spread of appendiceal, colorectal, peritoneal mesothelioma, gastric carcinoma, and more recently to gynecological malignancies. 1–3 CRS-HIPEC involves extensive peritoneal stripping, multi-organ resections, and the intraperitoneal administration of heated (up to 42°C) chemotherapy agents (eg, mitomycin C, cisplatin or oxaliplatin). 4 After CRS-HIPEC, acute pain can be severe and, in many patients, difficult to treat. 5 The current perioperative management of CRS-HIPEC related pain relies on multimodal analgesia strategies using regional anesthesia and systemic analgesics, including opioids. 6 , 7 Unfortunately, abdominal pain may remain undertreated for some patients, and can lead to the consumption of large amounts of opioids that can be as high 1000 mg of morphine equivalent daily. 7 , 8 In those patients, high opioid consumption is an independent risk factor for postoperative adverse outcomes, delayed recovery and persistent postoperative opioid use. 9 Ketamine is a N-methyl-D- aspartate receptor antagonist that at high doses has anesthetic effects but at low doses is a potent analgesic. 10 Ketamine has opioid-sparing effects and delays the time of first-time opioid dose after major surgery. 11 , 12 Clinical studies demonstrate that ketamine does not show significant clinical effects on the reduction of persistent postsurgical pain. 13 , 14 However, a randomized controlled trial by De Kock et al demonstrated that intravenous ketamine (0.5 mg/kg bolus followed by an infusion of 0.25 mg/kg per h) reduced analgesic use one, six and 12 months after open laparotomy. 15 We consider important to find strategies to effectively treat pain and reduce acute and long-term exposure to opioids after CRS-HIPEC. The impact of low intraoperative doses of ketamine on acute, persistent, and chronic pain and opioid use after CRS-HIPEC is unknown. Here, we tested the hypothesis that a low dose of intravenous ketamine intraoperatively is associated with a significant reduction in opioid use perioperatively and long term after CRS-HIPEC. This was a retrospective study approved by the Institutional Review Board (IRB) of the University of Texas MD Anderson Cancer Center (PA 14–0160). After obtaining waiver of informed consent and according to data confidentiality a -Abstract Truncated-
clinical neurology